Note: Descriptions are shown in the official language in which they were submitted.
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE I)E CETTE DEMANDE OU CE BREVETS
COMPRI~:ND PLUS D'UN TOME.
CECI EST ~.E TOME 1 DE 2
NOTE: Pour les tomes additionels, veillez contacter 1e Bureau Canadien des
Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
THIS IS VOLUME 1 OF 2
NOTE: For additional vohxmes please contact the Canadian Patent Oi~ice.
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
A NON-DENATURING PROCESS TO PURIFY RECOMBINANT PROTEINS
FROM PLANTS
FIELD OF THE INVENTION
The present invention is in the area of biochemistry and protein technology
and
relates to improved methods of isolation and purification of heterologous
proteins
from transgenic plant material.
BACKGROUND
Protein based biopharmaceuticals show great promise in providing more specific
and tissue specific, or cell specific drug treatments against serious diseases
(for
overview see "Recombinant Protein Drugs" Ed. P. Buckel 2001).
Numerous examples in the prior art and applications have demonstrated the use
of microorganisms such as bacteria, and animal cells for the production of
such
biopharmaceuticals, of which insulin is a notable example.
Many examples in the literature have demonstrated the utilization of
transgenic
plants or plant cell cultures for expression and manufacturing of high-value
heterologous polypeptides or biopharmaceuticals. Such plant-based
manufacturing process may be called molecular farming.
Production of valuable proteins can be made more economical by the use of
plants as production organisms. The cultivation cost for plants used as host
organisms for protein manufacturing can be considerably lower campared to most
production systems based on bioreactors, such as prokaryotic production
systems, animal cell cultivation and so forth. However, for all of the above
production systems, purification of heterologous proteins remains a demanding
and costly task. Thus, for plant-based production systems, downstream
processing generates most of the production costs in the manufacturing of high-
value heterologous proteins.
Protein purification and isolation is a key process in downstream processing
of
proteins accumulated and produced in a variety of host organisms by the use of
gene technology. The purification of proteins from the host organisms can be
1
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
quite laborious, complex and expensive. A variety of chromatographic
strategies
are used commercially for separation and purification of proteins of interest
from
production host organisms. The chromatographic strategies may rely on
physicochemical differences between contaminating or endogenous proteins and
the heterologous protein of interest, such as in size, solubility, charge,
hydrophobicity, and affinity.
Combinations of chromatographic strategies consisting of multiple steps,
require
several expensive chromatography matrices and the necessary hardware
consisting of columns, control units and so forth, and are accompanied by
product
yield-losses at each step, and consequently, economical losses. In addition to
the
chromatographic steps involved, downstream processing typically involves
multiple filtering and centrifugation steps. As a result, the cost of
purification and
downstream processing may become prohibitive for the purification of a protein
based biotechnological product. As for a number of protein-based products of
lesser value, such as industrial proteins, the cost of downstream processing
can
be inhibitory for their use and marketing, resulting in crude and poorly
defined
products. For most biotechnology products purification costs are certainly a
major
proportion of the manufacturing costs.
The cost of specialized chromatography matrices effecting the separation of a
protein of interest from contaminants is high ~as a result of complex coupling
chemistry involved in their production. Some common chromatography methods
are ion exchange chromatography, hydrophobic interaction chromatography and
reversed phase chromatography. Ligands coupled to a matrix may include a
variety of diethylaminoethyl- or quaternary aminoethyl groups as anion
exchangers and carboxymethyl substituents and sulfonate groups and phosphates
as cation exchangers of varying strength (Scopes, 1993), hydrophobic alkyl,
phenyl or butyl groups coupled to crosslinked agarose matrices for hydrophobic
interaction chromatography (Hydrophobic Interaction Chromatography (HIC) nr.
18-1020-90, Amersham Pharmacia Biotech), or hydrophobic n-alkyl groups as
ligands grafted to a porous, insoluble beaded matrices composed of silica or
synthetic organic polymers (Reversed phase Chromatography (RPC), Code nr. 18-
11134-16, Amersham Pharmacia Biotech) The chemical complexity of these
matrices may cause unwanted leaching of ligands and other substances from the
matrix during a purification procedure, where necessary preventive measures,
monitoring, or the removal of leachates from the protein of interest add to
the
already high cost of downstream processing.
2
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
Affinity chromatography is among the most powerful purification principles as
it is
based on specific affinity between an agent and a specific ligand, often
mimicking
a natural protein-ligand interaction. Several different kinds of affinity
adsorbents
are available, some highly specific for a particular protein, others binding
to
classes of proteins rather than particular proteins. In many cases affinity
chromatography implies the use of an immobilized ligand to an adsorbent that
specifically selects out proteins binding to that ligand. The coupling of
ligands to
affinity adsorbents involves the use of coupling chemistry such as cyanogen
bromide-, tosyl-, or vinylsulfone-activation of adsorbents. The ligand coupled
to
the column matrix may or may not be of proteinaceous origin. Examples of the
former are, but not limited to, immobilized protein A or protein G having
affinity
for ?-globulin, therefore being useful in the purification of antibodies, and
lectins
with affinity for glycoproteins. As an example of the latter, immobilized
glutathione coupled to matrix binds fusion proteins containing a glutathione S-
transferase domain. Immobilized metal affinity chromatography (IMAC) is based
on immobilization of metal-chelating ligands to a matrix and relies on the
formation of weak coordinate bonds between metal ions immobilized on a column
and basic groups on proteins, mainly histidine residues. Commercial cloning
vectors provide for cloning of a cDNA in frame with a string of histidine
residues -
a His-tag, that enables the purification of the resultant fusion protein with
IMAC.
Although widely used for small-scale purification of proteins, IMAC is a non-
specific but selective method, as native histidine residues in contaminating
proteins can lead to binding in IMAC (Scopes 1993). Several different kinds of
tags or binding domains are available in commercial expression vectors
resulting
in fusion proteins where the tag/binding domain binds the fusion protein to a
ligand coupled onto a column matrix.
High specificity of protein binding can be achieved with these matrix-ligand
systems. In the cases mentioned above, complex coupling chemistry is involved
to immobilize a ligand onto an inert matrix. Consequently, the cost of an
affinity
matrix can often become inhibitory to industrial scale applications of this
powerful
technique. Furthermore, as with most other types of chromatography methods,
the stability of the coupling of the ligand to the matrix becomes an issue and
leaching is of great concern. Heavy metal leaching in IMAC can cause
unacceptable and serious contamination in many sensitive purification
processes
for bioactive proteins, and may inactivate proteins being purified (Scopes
1993).
3
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
It is of particular relevance for the present invention that it is not
uncommon that
the binding affinity of a protein to its ligand is so strong that conditions
for
elution, to disrupt the ligand-protein binding, require drastic conditions
that partly
denature the valuable protein being purified. A non-limiting example of this
is the
elution of antibodies from Protein A-affinity matrix, requiring denaturing at
low pH
to release the antibody from the column. Including a denaturing step in a
protein
purification process is undesirable due to the risk of loss of activity of the
purified
protein, the addition of an extra step for refolding the protein and
subsequent
activity analysis requirements for the refolded protein product, and the added
IO cost involved.
To enable the use of affinity-based chromatography for large scale
purification
from plants, it is highly desirable to develop a non-denaturing protein
purification
process that is simpler and more economic than the current measures
commercially available, with less coupling chemistry involved and compatible
with
the quality requirements of the pharmaceutical industry standards.
Plant-based production of proteins shows great promise for large scale
manufacturing of proteins in an economic manner, as has been shown by
examples in literature (for overview see Hammond 1999). The cultivation costs
involved in molecular farming with plants are considerably lower than with
traditional bioreactor-based methods. Whereas upstream events in plant-based
production look particularly promising, the downstream processing is facing
the
same challenges as the rest of the protein production industry.
Polysaccharides and polysaccharide binding proteins may be used in conjunction
for the design of an affinity chromatography step (see, e.g., Boraston et al.,
2001).
In an example of prior art (U.S. Patent No. 6,331,416 ) Shani et al. describe
a
method of expressing a recombinant protein with a polysaccharide binding
domain that binds to the poorly defined cellulose in the host plant cell
walls, and
a protein purification process utilizing the affinity of this protein to host
plant
cellulose, resulting in a cell wall-protein complex that can be separated from
soluble contaminating proteins. The strength of binding can be such that
releasing
the protein from the cellulosic host plant matter may require drastic
conditions
that denature the protein, having negative effects on the activity of the
recombinant proteins being purified. Thus, although presenting a way to purify
4
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
proteins from plant material the harsh conditions required for disrupting the
ligand/cell-wall binding involve complications and concerns comparable to
those
mentioned above for antibody-Protein A elution.
To enable the use of affinity-based chromatography for large scale
purification
from plants, it is highly desirable to develop a non-denaturing protein
purification
process that is simpler and more economic than the current measures
commercially available, with less coupling chemistry involved and compatible
with
the quality requirements of the pharmaceutical industry standards.
The carbohydrate binding domain CBM9-2 is from the Thermotoga maritima
Xylanase 10A (Winterhalter et al 1995: Mol. Microbiol. 15 (3), 431-444). The
CBM9-2 genomic DNA sequence is available as GenBank Accession No. 246264
and it belongs to the Family IX of CBM-s and has number of attractive
properties
for high-resolution affinity purification, including non-denaturing eluting
conditions using 1M glucose as a eluent, and high specific affinity for
amorphous
as well as crystalline celluloses (Boraston et al. 2001: Biochemistry 40, 6240-
6247).
Recovery and purification of expressed recombinant proteins from transgenic
plants is probably the most critical factor in establishing plants as a
practical
alternative system for protein production. It is essential that the number of
processing steps be minimized and that each step be carried out at much higher
efficiencies. (Moloney 2000)
This emphasizes a recognized need for a downstream process for purification of
heterologous proteins from transgenic plant material that is efficient,
simple, and
economical. Furthermore, there is a need for such a downstream process
consisting of gentle, non-denaturing conditions for the protein of interest,
(in
particular, specific affinity purification methods with gentle elution
conditions) in
order to secure bioactivity of the protein of interest, and improve yields.
A non-denaturing protein purification process free from the imitations
detailed
above could significantly lower the production cost involved in the production
of
biopharmaceuticals from plants, and would be enabling for the purification of
heterologous proteins of value for which downstream processing has been
prohibitively complex and costly.
5
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
SUMMARY AND OBJECTS OF THE INVENTION
The primary objective of present invention is to provide an improved, non-
denaturing method for protein purification of high-value heterologous proteins
produced in plants, plant derived tissue or plant cells.
The invention aims to reduce the cost and improve the quality of downstream
processing of heterologous proteins produced in plants.
An important step in the purification process is the separation of the protein
of
interest as a CBM-fusion protein from cell-wall fragments and other poorly
defined plant-derived solids as the CBM-fusion protein of the invention does
not
bind to these components. This can be done separately prior to an affinity
chromatography step or simultaneously with an affinity chromatography step.
In a first aspect, the invention provides a non-denaturing method for
production
and purification of a soluble heterologous fusion protein comprising a
cellulose
binding module (CBM), from transgenic plants or transgenic plant cells
expressing
said fusion protein, the method comprising:
disrupting the transgenic plant material;
adding an extraction liquid to the plant material, thereby creating a
mixture of soluble and insoluble plant material, so as to extract the soluble
fusion
protein from said disrupted plant material to the liquid phase to obtain a
protein
extra ct;
separating the insoluble plant material, comprising cell-wall material and
solids, from said protein extract comprising said fusion protein of interest;
contacting said protein extract to a polysaccharide matrix which binds to
said fusion protein;
washing the matrix with the bound fusion protein with one or more
suitable aqueous solutions such as one or more buffer solutions, i.e., the
washing
may be preformed in one step, with a gradient or as a sequence of different
washing solutions; and
eluting the fusion protein from said polysaccharide matrix by adjusting
conditions effecting the release of said fusion protein from the matrix under
characteristically mild conditions.
6
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
Typically, the transgenic plant or plant cell is selected from the group of
dicotyledonous plants and monocotyledonous plants, and in preferred
embodiments said plant cell or transgenic plant is from the group of tobacco,
rape
seed, soy bean, lettuce, alfalfa, barley, maize, wheat, oat and rice.
The separation step comprises in some embodiments a method selected from
expanded bed adsorption (EBA), packed mode chromatography, precipitation,
filtration, centrifugation, or any combination thereof.
The affinity binding step binding the fusion protein to a polysaccharide
matrix
preferably comprises a chromatography step.
However, in certain useful embodiments, said separation of cell-wall fragments
and other poorly defined plant-derived solids from the protein of interest -
the
CBM-fusion protein, and the affinity binding of the CBM fusion protein to a
polysaccharide matrix can be done in a single powerful purification step using
Expanded Bed Adsorption chromatography (EBA) with a suitable, inexpensive
polysaccharide matrix. This feature streamlines and improves the economy of
the
downstream processing.
In advantageous embodiments of the present invention, the polysaccharide
matrix comprises cellulose, and preferably pharmaceutically compatible
cellulose.
Such a well-defined pharmaceutical grade cellulosic matrix to which the CBM-
fusion protein binds allows various high-end uses of the purified heterologous
protein. A useful pharmaceutically compatible cellulose material for use as
the
polysaccharide matrix comprises AviceIT"' (FMC Corporation, PA, USA).
The polysaccharide matrix used for affinity chromatography according to the
invention requires no complex coupling chemistry or immobilization of
potentially
30~ leaching ligands. The polysaccharide matrix provides both structural
support and
rigidity while constituting the affinity adsorbent itself. Thereby, more
economical
and safer protein purification is enabled for plant derived heterologous
proteins.
It is still an advantage of 'this invention that the process described is
amenable for
different polysaccharide matrices of differing qualities all according to the
different end-use of the purified heterologous proteins e.g. in for example
agriculture, chemical industry or pharmaceutical industry. An affinity
adsorbent
,,
made out of polysaccharide of pharmaceutical grade is a bulk material within
the
7
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
pharmaceutical industry and is considerably less expensive than any
commercially
available affinity chromatography media. Thus, an affinity matrix of very high
quality can be made economical using the process described by this invention,
enabling more economical downstream processing of high-value proteins from
$ plant derived material.
It is a further advantage of the present invention that once the plant derived
CBM-fusion protein is bound to the polysaccharide chromatography matrix, and
after washing the matrix to remove any contaminating endogenous plant
proteins, the fusion protein can be eluted from the column using non-
denaturing,
mild conditions typically under neutral or acidic conditions and preferably
with the
addition of soluble carbohydrates (sugars), that preserve the activity and
structure of any fusion partner protein attached to CBM. The sugars compete
with
cellulose for the binding site of the CBM and a suitable concentration will
release
substantially all of the bound CBM fusion protein.
It follows that the preferred CBM-s that are used in the methods of the
invention
and fused to the heterologous protein of interest are such CBM-s that have
desired binding characteristics to allow sufficiently strong binding to a
suitable
polysaccharide matrix to obtain a high yield of bound CBM fusion protein, and
releasing by such mild conditions as described above. CBM9-2 has been found to
have these desired characteristics. The use of other CBM-s with such
characteristics is also within the scope of the invention. Such CBM-s may be
found e.g. by searching available gene databases for sequences encoding CBM
having desired characteristics, e.g. sequence motifs found to be similar to
motifs
in CBM9-2 that are important for the,,binding characteristics. Also, existing
CBM-s
may be modified with point mutation techniques well known in the art to modify
their binding characteristics in order to obtain suitable CBM-s according to
the
invention.
After the fusion protein has been eluted from the polysaccharide affinity
matrix it
may optionally be subjected to one or more further purification or isolation
steps,
depending on the desired form and use of the protein.
In useful embodiments, the transgenic plant or plant cell comprises a nucleic
acid
sequence encoding for a CBM, preferably the CBM is heat-stable and remains
soluble at elevated temperatures. The term heat-stable in this context
indicates
that the protein remains soluble, correctly folded and active at elevated
8
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
temperatures, i.e. temperatures above about 25°C, and typically above
about
37°C, including the range of 40°C -100°C.
Genes encoding such preferred CBM may be obtained from thermophilic
organisms, including thermophilic bacteria, algae and fungus and introduced
into
the host plant or plant cell in such a way as to express a fusion protein
comprising said CBM. The term thermophilic refers herein to organisms with
optimal growth temperature over 40°C. A preferred CBM is coded for by
the
xylanaselOA gene from Thermotoga maritima, preferably the region within the
host plant or plant cell that codes for a CBM is a region of said gene. Said
region
coding for a CBM may in certain embodiments comprise a sequence depicted as
SEQ ID NO: 1, or a nucleic acid sequence encoding the same amino acid
sequence, or a sequence encoding an amino acid sequence with substantial
sequence identity to said amino acid sequence.
It may be useful in some embodiments of the invention to heat the protein
extract comprising the soluble fusion~Iprotein, such as to a temperature in
the
range of 37°C and 100°C, e.g. a temperature in the range of 50-
80°C, for a
period of time such as in the range of from 1 min to 120 minutes during the
process. For this purpose, heat-stable CBM such as from thermophilic sources
is
particularly useful. In some useful embodiments, the heat-stable CBM may
promote solubility of attached heterologous protein at elevated temperatures,
a
feature that may be used for CBM-fusion protein enrichment of an extract
containing other heat labile plant proteins. During such heating, a part of
the
endogenous plant proteins may become inactivated and/or denatured and may
thus readily be separated from the protein extract. Said heated extract may
preferably be subjected to the process step comprising expanded bed adsorption
with a polysaccharide matrix for the simultaneous separation of solids and
affinity
binding of said CBM fusion protein from the heated extract.
In a highly useful embodiment of the~,invention, said fusion protein comprises
a
CBM and a heterologous polypeptide of interest intercepted by a stretch of
amino
acids comprising a proteolytic cleavage site, preferably a proteolytic
cleavage site
recognized and cleaved by a specific protease. By having such a site, the CBM
can
readily be cleaved off the fusion partner in the fusion protein to obtain the
desired
purified heterologous protein without the accompanying CBM. Detailed
description
for such successful purification involving a specific protease is disclosed in
applicant's co-pending application ~~ A process for proteolytic cleavage and
9
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
purification of recombinant proteins" which application is filed
simultaneously with
this application and is incorporated herein in full by reference.
The present invention successfully addresses the short-comings of downstream
processing involved in of heterologous protein production at large scale, for
purposes such as, but not limited to, agriculture, chemical industry and the
production of protein-based pharmaceuticals. In particular, it provides a
novel
process of separating CBM-fusion proteins from biomass such as plant-derived
cellulosic material, with fewer processing steps involved, taking advantage of
a
safer and more economical affinity chromatography principle amenable for use
within the pharmaceutical industry, gentle elution conditions maintaining the
activity of high-value heterologous proteins, and in applicant's co-pending
application's A process for proteolytic cleavage and purification of
recombinant
proteins" comprising a process step enabling the recycling of a specific high-
value
protease in the process.
BRIEF DESCRIPTION OF DRAWINGS
Figure 1 is a schematic diagram of a preferred embodiment of the purification
process.
Figure 2 demonstrates the results obtained from Example 1 by SDS-PAGE
analysis. Lane 1: molecular weight size markers, lane 2: purified CBM9-2, lane
3:
washed solids from milled barley seed, lane 4: supernatant after biomass
interaction, lane 5: first wash with low salt buffer, lane 6: fifth wash with
high salt
buffer.
Figure 3 demonstrates the successful purification of CBM9-2 from milled barley
seed extract according to the method of this invention, as described in detail
in
Example 2. The figure shows the chromatographic profile of an expanded bed
absorption (EBA) column with 200 mL cellulose.
Figure 4 demonstrates the results obtained from Example 3, Heat stability and
enrichment of CBM9-2 in extracts. The figure shows a SDS-PAGE analysis of heat
stability of CBM9-2 in barley extracts subjected to different temperatures.
Lane 1:
molecular weight size markers 10-200 kDa, lane 2: barley seed extract at room
temperature (RT), lane 3: purified CBM9-2 (RT), lane 4: CBM9-2 + barley seed
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
extract (50°C), lane5:. CBM9-2 + barley seed extract (60°C),
lane 6: CBM9-2 +
barley seed extract (70°C), lane 7: CBM9-2 + barley seed extract
(90°C).
Figure 5 demonstrates results obtained from Example 4. The graph shows ELISA
readings of a control sample and a minimal reading of sample containing a
heterologous protein of interest (HoxB4) fused to CBM9-2 and purified
according
to the down-scaled version of the purification process described herein. The
columns show the measured ELISA values for (a) elution buffer, (b) fusion
protein
extracted from transgenic seeds, and (c) protein extracted from non-transgenic
seeds.
DETAILED DESCRIPTION OF PRESENT INVENTION
Herein below, the present invention will be described in more detail.
Unless defined otherwise, ali technical and scientific terms used herein have
the
same meaning as is commonly understood and used by one of skill in the art to
which this invention belongs,
The term "polypeptide" used herein refers to any polymer of amino acids, being
monomeric or multimeric, and does not refer to a specific length of a polymer
of
amino acids. Thus, for example, the terms peptide, oligopeptide, protein, and
enzyme are included within the definition of polypeptide. This term also
includes
polypeptides with post-expression modifications such as for example,
glycosylations, acetylations, phosphorylations and the like.
The term "heterologous polypeptide of interest" or "polypeptide of interest"
used
herein refers to any polypeptide intended for expression in plant-cells or
plant
tissue using the methods or compositions of the present invention. As non-
limiting examples, pharmacological polypeptides (e.g., for medical uses) or
industrial polypeptides (e.g. enzymes) can be produced according to the
present
invention.
The term "downstream processing" refers to the isolation and purification of a
biotechnological product to a form suitable for its intended use.
The term "fusion partner" refers herein to a heterologous protein linked to
CBM.
11
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
Figure 5 demonstrates results obtained from Example 4. The graph shows ELISA
readings of a control sample and a minimal reading of sample containing a
heterologous protein of interest (HoxB4) fused to CBM9-2 and purified
according
to the down-scaled version of the purification process described herein. The
columns show the measured ELISA values for (a) elution buffer, (b) fusion
protein
extracted from transgenic seeds, and (c) protein extracted from non-transgenic
seeds.
DETAILED DESCRIPTION OF PRESENT INVENTION
Herein below, the present invention Uvill be described in more detail.
Unless defined otherwise, all technical and scientific terms used herein have
the
same meaning as is commonly understood and used by one of skill in the art to
which this invention belongs.
The term "polypeptide" used herein refers to any polymer of amino acids, being
monomeric or multimeric, and does not refer to a specific length of a polymer
of
amino acids. Thus, for example, the terms peptide, oligopeptide, protein, and
enzyme are included within the definition of polypeptide. This term also
includes
polypeptides with post-expression modifications such as for example,
glycosylations, acetylations, phosphorylations and the like.
The term "heterologous polypeptide of interest" or °polypeptide of
interest" used
herein refers to any polypeptide intended for expression in plant-cells or
plant
tissue using the methods or compositions of the present invention. As non-
limiting examples, pharmacological polypeptides (e.g., for medical uses) or
industrial polypeptides (e.g. enzymes) can be produced according to the
present
invention.
The term "downstream processing" refers to the isolation and purification of a
biotechnological product to a form suitable for its intended use.
The term "fusion partner" refers herein to a heterologous protein linked to
CBM.
12
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
The term "CBM fusion protein" refers~~to a molecule consisting of a CBM linked
to
a heterologous protein, and in the context it is put forward in this
invention, a
molecule without a proteolytic cleavage site, unless described otherwise.
The term "operably linked'° refers to a functional linkage between a
promoter
(nucleic acid expression control sequence, or array of transcription factor
binding
sites) and a second nucleic acid sequence, wherein the promoter directs
transcription of the nucleic acid corresponding to the second sequence.
The term °denatured" refers to a condition of a protein where the
native
structure, and consequently the activity of the protein is disrupted, and the
protein is unfolded or incorrectly folded changing its native three-
dimensional
structure.
The term "expression" and "production" refer to the biosynthesis of a gene
product, including the transcription and translation of said gene product.
"Molecular farming" refers to the operation of using plants of any kind in
open
fields or in closed facility to express and produce heterologous proteins in
their
tissue
The term "transgenic" refers to a any cell, cell line, tissue plant part,
organ or
organism into which a non-native nucleic acid sequence has been introduced,
and
therefore altering its genotype, as is progeny thereof in which the non-native
nucleic acid is present. Typically, the non-native nucleic acid sequence was
introduced into the genotype by a process of genetic engineering, or was
introduced into the genotype of a parent cell or plant by such a process and
is
subsequently transferred to later generations by sexual crosses or asexual
propagation.
"Substantial sequence identity" indicates in the context herein at least 50%
sequence identity and more preferably at least 60% such at least 70 sequence
identity, such as at least 80% and preferably at least 90% sequence identity,
such as at least 95% or 99% sequence identity. Algorithms for sequence
analysis
are known in the art, such as BLAST, described in Altschul et al., J. Mol.
Biol.
(1990) 215:403-10. Generally, the default settings with respect to, e.g.
"scoring
matrix" and "gap penalty" will be used for alignment.
13
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
The term "transformation" or °transformed" refers to the introduction
of a nucleic
acid sequence into the DNA genome of a host organism, irrespective of the
techniques used for the introduction of the nucleic acid fragment into the
host
cell.
"Thermophilic" refers to an organism with optimal growth temperature over
45°C.
The term °GMP" (good manufacturing practice) dictates the manner
in which
biopharmaceuticals and other drugs and medical devices are produced. GMP
requirements include standard operating procedures, sterile conditions,
validation
of materials and equipment and trained personnel.
Monocotyledonous and dicotyledonous plants that can be genetically manipulated
can be used in the present invention. Preferably the plant is a
monocotyledonous,
more preferably barley, and most preferably the barley Hordeum vulgaris. A
plant
that can be genetically transformed is a plant into which non-native DNA
sequence, including DNA sequence for a coding region, can be introduced,
expressed, stably maintained, and transmitted to subsequent generations of
progeny. Genetic manipulation and transformation methods have been used to
produce barley plants that are using herbicides including, for instance,
bialaphos
or basta, or antibiotic, such as hygromycin, as selectable markers.
M ETH ODS
Additional objects, advantages, and novel features of the present invention
will
become apparent to one ordinarily skilled in the art upon examination of the
following examples, which are not intended to be limiting. Additionally, each
of
the various embodiments and aspects of the present invention as delineated
hereinabove and as claimed in the claims section below finds experimental
support in the following examples.
Although only preferred embodiments of the invention are specifically
illustrated,
numerous modifications and variations in the invention as described in the
above
examples are expected to occur to those skilled in the art, without departing
from
the spirit and intended scope of the invention.
14
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
Referring to Fig. 1 illustrating a schematic diagram of the purification
process the
process can be described as follows:
(i) The starting material for the process is a transgenic plant, material
derived from transgenic plants or transgenic plant cells, including, but
not limited to, suspension cultures of plant cells as well as
undifferentiated cells of calluses. The material is transgenic in a way that
it expresses in a controlled manner a heterologous genes) operably
linked to a CBM open reading frame, that have been introduced to the
plant cells through processes known to a person skilled in the art, such
as, but not limited to, Agrobacterium-mediated transformation or particle
bombardment-mediated transformation or plant viral vector-mediated
transformation. The starting material is preferably selected on the basis
of satisfactory expression levels of the fusion protein, as deemed by an
analysis of RNA or protein levels by a person skilled in the art, prior to
the initiation of the process described by the invention.
(2) Disruption of the transgenic material is accomplished by any method
known to a person skilled in the art, that results in homogenization of
the plant tissue and plant cells, in a dry or wetted state. A variety of
methods can be chosen from, that suit the source of the plant material.
Thus, for seeds, milling is a good way of disrupting the transgenic plant
tissue, while for leaves and softer green tissue homogenizing can be
accomplished with equipment such as, but not limited to, Waring
blender, Sorvall Omnimixer or Polytron homogenizers. The equipment for
disruption of plant tissue and plant cells is commercially available and
easy to scale up as required. General methods of extraction of proteins
from plant sources are described by G. Paul Powell in a publication
edited by S. Roe, Protein purification applications, 2nd edition (2001). A
simple and successful method of extraction of soluble proteins from plant
sources is the addition of simple buffers like Low salt buffer to the
disrupted, homogenized plant tissue, with thorough mixing. Precautions
against oxidative tanning, such as addition of polyvinyl pyrrolidine (1%
w/v) are usually sufficient to optimize purification from most plant
tissues in order to sequester phenolics from the plant tissue that
otherwise could have negative effects on the heteroiogous protein to be
purified. Proteolysis does not always cause problems with plant sources.
If, however, proteolysis is a concern, protease inhibitors, such as, e.g.,
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
serine-, cysteine- and metalloprotease inhibitors can be added to the
extraction buffer. The disruption of the plant material can be done in the
presence or absence of a buffered solution. The extraction solution may
or may not contain reducing agents such as, but not limited to 2-
S mercaptoethanol or dithiothreitol (DTT). Soluble plant proteins will be
present in the liquid phase together with the CBM-fusion proteins
(3) Mixing of liquid with plant material is essential to extract the water-
soluble fusion protein to the liquid phase. The liquid added may or may
not contain buffering agents to control pH, preferably within the range of
about 5.2 to 8.3, it may or may not contain any reducing agents or
sequestering agents as described in (2) accordingly to the protein of
interest. In its simplest form, the liquid can be water. After thorough
mixing of liquid with the disrupted and homogenized plant material, the
liquid phase now contains the CBM-fusion protein.
1S (4) (A) Depending to some degree on the level of homogenization the
mixture of disrupted plant material and extraction liquid can be applied
directly to an Expanded Bed Adsorption (EBA) column. In this approach
the mixture is applied to the column as a stream of fluid through an
expanded bed of affinity adsorption matrix of polysaccharide nature.
During the streaming through the column the fusion protein in the liquid
phase is exposed to the polysaccharide matrix and is selectively .
adsorbed through the selective affinity of the CBM to the polysaccharide
adsorbent media. Particles such as, but not limited to, cell wall
fragments and other solids, together with any soluble plant proteins are
2S flushed through the EBA column in the flow-through liquid.
4(B) Alternatively, a majority of the solids in the mixture can be
separated from the liquid prior to the affinity binding step through a
variety of methods known to a person skilled in the art, these include,
but are not limited to, precipitation, filtration, centrifugation, and
sedimentation. As described hereinabove, the solids are discarded and
the liquid containing the CBM-fusion protein is subjected to an optional
heating step 4(C) or applied directly to the affinity binding step (5).
4(C) Heating of the mixture or liquid prior to affinity step (5) is optional,
but may act, as an additional purifying step in cases where the CB,M-
3S fusion protein as a whole remains soluble at elevated temperatures,
while soluble plant proteins may denature and precipitate and
endogenous plant proteases may be inactivated through heat. For this
purpose, the heating procedure, taking into account the nature of the
16
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
CBM-fusion protein, may involve heating in the range of 50°C to
100°C,
for a period of time in the range of 2 min to 60 minutes during the
process. In these embodiments CBM of thermophilic origin are
particularly beneficial.
(5) Affinity binding to matrix. The liquid protein extract containing the
plant derived CBM-fusion protein is brought into contact with the
polysaccharide matrix towards which the CBM has affinity for. The
contact can be effected in various ways, such as, but not limited to,
chromatography columns packed with the polysaccharide matrix where
the liquid is run through the column in either packed or expanded mode,
referring to the density of the polysaccharide matrix, or it can be
effected in batch mode where the polysaccharide matrix is mixed
together with the liquid in a suitable container, with the subsequent
recovery of the matrix and the adsorbed CBM-fusion protein. The
polysaccharide matrix can be of cellulosic origin such as, but not limited
to, Avicel, or it can be of xylanoic origin, such as insoluble xylan. The
binding specificity and thermodynamics of CBM9-2 have been studied in
detail in a recent publication by Boraston et. al. (2001). It has however
surprisingly been found by the present inventors, in contrast to what is
indicated in the prior art, that following the methods of the present
invention as described herein, CBM9-2 does not bind to plant cell waft
components but becomes readily soluble, while retaining good specific
binding to a polysaccharide matrix such as used in the affinity adsorption
step herein (5). As described herein above this surprising quality
introduces several advantages to downstream processing of plant
derived CBM-fusion proteins to the extent that a greatly improved
downstream processing method is provided.
(6) Washing of the matrix. The polysaccharide affinity adsorbent with
CBM-fusion protein bound to it can be washed with several column
volumes (relevant quantitative term if the affinity matrix is placed in a
chromatography column) of an aqueous solution (e.g.. water) or buffer,
such as, but not limited to phosphate buffered saline or Tris-based
buffers. To improve the efficiency of the washing step, the composition
of the washing buffer may be adjusted by means such as, but not limited
to, several column volumes of stepwise changes or a gradient of salt
concentration or detergent, used to release weakly but nonspecifically
bound contaminating proteins from the matrix.
17
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
(7) Release of fusion protein from matrix. By using CBM-s with the
desired binding characteristics as described herein, elution of the CBM-
fusion protein from the affinity matrix can be effected with the exposure
of the CBM-fusion protein to competing saccharides such as, but not
limited to glucose, galactose, lactose, maltose, and cellobiose. Any of
these or other similar saccharides, or a combination thereof, can be
added in a suitable amount, such as in the range of imM to 1 M
concentration to an elution buffer such as, e.g., phosphate buffered
saline or Tris-based buffers, for the elution step. The saccharide
concentration can be e.g. in the range 25 mM to 1 M, such as in the
range 50 - 500 mM. These saccharides are commercially available as
low-cost bulk chemicals, further improving the overall economy of the
downstream processing according to the invention.
(8) Isolation/purification of fusion protein. Further purification/isolation
of the CBM-fusion protein may be advantageous or required be in some
instances. Such further isolation can be accomplished with any of the
commonly available chromatographic procedures known to a person
skilled in the art, such as, but not limited to, ion exchange
chromatography or size exclusion chromatography.
(9) Final product. The final product is in this case a CBM-fusion protein in
a highly purified form, ready for optional proteolytic cleavage of the CBM
-fusion protein or further purification/isolation that may be required or
be advantageous in some instances. This further isolation can be a
chromatography step, such as, e.g., ion exchange chromatography or
size exclusion chromatography.
The highly purified form is ready for further formulation and packaging in
its final form, if necessary.
Additional objects, advantages, and novel features of the present invention
will
become apparent to one ordinarily skilled in the art upon examination of the
following examples, which is not intended to be limiting. Additionally, each
of the
various embodiments and aspects of the present invention as delineated
hereinabove and as claimed in the claims section below finds experimental
support in the following examples.
EXAMPLES
18
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
EXAMPLE 1
Biomass interaction study~ CBM9-2 and milled barley seed
Dried barley seed was finely ground in a Retsch mill to a fine flour. 1 g of
milled
seed was used for the extraction of water-soluble components from the seed
with
5 ml of low salt buffer (50 mM potassium phosphate buffer pH 7.02), as a means
to rid the sample of all water-soluble components that might interfere with
the
biomass interaction study. The mixture was vortexed and tumbled for 5 minutes
to ensure thorough mixing of the liquid and the milled barley seed material.
Following this mixing, the samples were centrifuged at 5000 x g for 4 minutes
to
pellet the solids. After centrifugation, the supernatant was discarded. This
procedure was repeated 3 times with low salt buffer, with the supernatant
discarded after each centrifugation. Then the washing procedure was repeated 3
times with high salt buffer (50 mM potassium phosphate buffer pH 7.02, 1 M
NaCI), the supernatant discarded as before. The resulting washed solids
representing for the most part plant cell-wall fragments and insoluble starch.
The washed solids were equilibrated with 3 times washing with low salt buffer
as
described above, to obtain same conditions that favor affinity binding of CBM9-
2
to cellulosic matrix in affinity chromatography. A representative sample of
the
solids before biomass interaction study was taken for SDS-PAGE analysis (lane
3). 10 p1 of bacterially produced CBM9-2 purified on cellulose (AviceIT'")-
affinity
column (0.D. @280 nm 0,394), were taken for later SDS-PAGE (lane 2). The
purified CBM9-2 had previously been subjected to repeated (4x) dilution and
concentration in a ultrafiltration module as a proven method for desorbing any
bound glucose from the CBM9-2, so as to regain the cellulose binding affinity
characteristic of the protein.
2 ml of the purified CBM9-2 were added to the washed, equilibrated solids
derived
from milled barley seed and the mixture incubated while shaking for 60 minutes
at room temperature. After incubation, the mixture was spun down at 5000 x g
for 10 minutes, and the supernatant subsequently clarified with centrifugation
at
13.000 x g for 5 minutes. 10 NI of the clarified supernatant from i:he biomass
interaction was taken for SDS-PAGE analysis (lane 4). Subsequently the pellet
consisting of the milled barley seed solids, was washed 5 times with low salt
buffer and subsequently 5 times with high salt buffer as described above. 10
p1 of
the first low salt buffer wash (lane 5) and the fifth low salt buffer wash
(lane 6),
were prepared for subsequent SDS-PAGE analysis. To elute any bound CBM9-2
from the milled barley seed solids, 1 ml of elution buffer (1 M glucose in 50
mM
KP04, pH 7.02 ) was added to the solids and incubated during mixing for 15
minutes, before centrifugation at 50d~0 x g for 5 minutes and removal of the
19
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
supernatant (eluate). A i0 NI sample of the eluate was prepared for SDS-PAGE
analysis (lane 7). A representative sample from the solids after the biomass
interaction study and elution was taken for SDS-PAGE analysis (lane 8). The
samples from the biomass interaction assay prepared for SDS-PAGE were run on
12.5 % SDS-PAGE gels (PhastGels homogenous 12,5) using PhastSystem
(Amersham Pharmacia Biotech). After completion of the run the gel was stained
with Coomassie Blue R-250, and destained. The results are illustrated in FIG.
2.
These results demonstrate that CBM9-2 does not bind significantly to plant
derived cell-wall fragments or other insoluble solids from milled barley seed.
EXAM PLE 2
Purification of CBM9-2 from milled barl~i seed extract
Barley seeds were milled to finely ground flour using commercially available
mill
(Aarslev Maskinfabrik, Erhvervsvangen 11, 5792 Aarslev, DK). The resulting
barley flour was wetted in Low salt buffer (50 mM potassium phosphate buffer
pH 7.02 ) in volume-ratios 2:3, barley flour: buffer, respectively. The liquid
was
mixed thoroughly with the flour in a vessel and allowed to sediment overnight
at
4°C. CBM9-2 purified from bacteria was added to the barley seed-
supernatant.
The next~day the spiked supernatant (100 ml) containing CBM9-2 was fed to to a
Streamline 25 (Amersham Biotech) chromatography column containing cellulose
(AvicelT'"). The feed application was done at flowrate 184 cm/h, in expanded
bed
mode, followed by a washing step with 5 column volumes high salt buffer (1 M
NaCI in 50 mM KPO4, pH 7.02), followed by 5 column volumes of low salt buffer
(50 mM KPO~, pH 7.02). The expanded column bed was allowed to sediment
(sedimented bed height = 20 cm) and elution was performed at 92 cm/h with 300
ml of elution buffer: 1 M glucose in 50 mM KPO~, pH 7.02). The elution
conditions
resulted in a small peak containing the CBM9-2 protein (see Fig. 3).
This showed that using the procedure described hereinabove that firstly; CBM9-
2
remains in solution unattached to cell-wall fragments and other poorly defined
solids from milled barley seed, secondly; it is possible to use
polysaccharidic
affinity chromatography as described by this invention to capture CBM 9-2 from
milled barley-seed extract, thirdly; this can be done by using well defined
pharmaceutical grade cellulose (Avicel) as a matrix, and fourthly; the
affinity
chromatography step can be done in expanded bed mode as described by the
invention, fifthly; the CBM9-2 purified from barley seed-extract can be eluted
of
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
the matrix under gentle conditions avoiding any denaturing steps, as described
by
this invention. The very same conditions and procedure as described
hereinabove,
can be applied to purify CBM9-2-fusion proteins from transgenic milled seed.
The polysaccharidic affinity chromatography described is also valid for the
separation of protease-CBM and excised CBM from the protein of interest after
a
proteolytic cleavage reaction, as described by this invention.
EXAMPLE 3
Heat stability and enrichment of CBM9-2 in extracts.
to
1.5 grams of milled barley were dissolved in 7.5 ml of Low salt buffer (50 mM
ICP04, pH 7.02). The solution was continuously mixed in a tumbler for 1 hr.
And
spun down at 6000 rpm for 10 minutes. The supernatant (extract) was measured
for protein content with Bradford assay and found to contain 1,93 mg/ml of
soluble seed proteins. 350 p1 of extract were mixed with 350 NI of purified
CBM9-
2 protein (0.238 mg/ml) and aliquoted to Eppendorf tubes that were
subsequently exposed to different temperatures (room temperature, 50°C,
60°C,
70°C and 90°C) in a water bath for 10 minutes. After heat
treatment the samples
were spun down at 11.000 rpm for 10 minutes and samples from the different
heat treatments analysed by SDS-PAGE. The.samples from the heat stability test
were prepared for SDS-PAGE and run on 12.5 % SDS-PAGE gels (PhastGels
homogenous 12,5) using PhastSystem (Amersham Pharmacia Biotech). After
completion of the run the gel was stained with Coomassie Blue R-250, and
destained. The results are illustrated in FIG. 4. Further tests on the CBM9-2
exposed to heat confirmed that its ability to bind to cellulose was not
adversely
affected in anyway by the exposure to heat.
The results show that while soluble barley seed proteins were gradually lost
from
solution CBM9-2 remained soluble during the entire temperature range. This
shows heat may be advantageously applied for the purpose of enrichment of CBM
and CBM-fusion proteins during extrdction stage of the purification process
described by this present invention.
EXAMPLE 4
Purification of heteroloaous protein attached to CBM9-2 from milled, sinctle
barley
seed extract.
In a down-scaled version of the purification procedure described hereinabove,
single seeds of transgenic barley plants expressing heterologous protein of
21
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
at room temperature for a period in the range of 30 sek toy min. When blue
color
had developed, 100 NI of 0.2 M Sulfuric acid was added. The color turned
yellow,
and the absorbance was measured in a microplate reader at 450 nm.
Results from an ELISA analysis of a single seed extraction from indivual
transgenic barley seed are shown in Fig. 5.
The ELISA analysis, previously shown to be specific for CBM9-2, shows firstly;
that heterologous fusion protein accumulation in individual seeds can be
achieved
and verified; that the procedure described hereinabove works for the isolation
of
a heterologous fusionprotein with cleavage site, even at small scale,
supporting
the scaleability of the purification process; it shows that heterologous
protein of
interest attached to CBM9-2 is succesfully maintained in solution during
extraction and not lost due to binding to poorly defined plant cell wall
cellulose; it
shows that the heterologous fusionprotein is not exposed to denaturation
during
the chromatography process, as it is recognized after elution by the specific
antibodies without any renaturation steps being involved, emphasizing the
advantage of the present invention to several other harsher affinity
chromatography procedures, as discussed hereinabove; that the purification
procedure described hereinabove is applicable to any heterologous fusion
protein
attached to CBM9-2.
EXAMPLE 5
Purification and activity measurements of CBM-protease
In order to produce a site-specific protease with a CBM9-2 tag attached to it
the
following procedure was followed:
Agrobacterium tumefaciens strain AGLO was constructed to contain a binary
plasmid carrying an expression construct composed of a constitutive promoter
in
front of enterokinase cDNA to which was attached cDNA corresponding to CBM9-
2, a signal sequence for targeting to Endoplasmic reticulum (ER) and a
retention
ignal to maintain the protein in the ER. This agrobacterium strain was grown
in
YEB media under selection conditions, first in 10 ml for 2 days at 28°C
up to O.D.
600 of 0.8. The small culture is diluted 1:50 to 500 ml culture containing 20
pM
acetosyringone for 2-3 days at 28°C and vigorous shaking up to O.D. 600
nm of
2.5. The bacteria was spun down at 6.000 rpm for 10 minutes and resuspended
in MS-solution (containing 55 g/1 sucrose) to OD600 2.5. Acetosyringone was
added (10 mM), for final concentration of 200 uM. Bacterial suspension was
then
22
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
kept at room temperature for 1 hour and Tween-20 (10%) added, for final
concentration of 0.005%.
For transient expression of CBM-protease in lettuce plants were submerged into
a
bowl containing the Agrobacterium bacterial suspension for 15 seconds.
Subsequently the plants were placed in a vacuum chamber and 0.4 bar pressure
was applied for 20 minutes, after which air inlet was opened to equalize
pressure
rapidly. The excess bacteria on leaf surface was washed off with successive
dipping into bowls of tap water. The lettuce plants were placed in a growth
chamber with 16 hrs day/8 hrs night light period at 22°C, for 4 days.
The plants were harvested by excising the leafy tissue and subsequently frozen
and kept at 86°C. The plants were homogenized using mortar and liquid
nitrogen
until a very fine powder was obtained. The powdered lettuce leaf material was
extracted by the addition of 1.2:1 (vol:vol) low-salt extraction buffer and
lettuce
powder respectively, and proteins extracted for 30 minutes with occasional
mixing at room temperature.
The extract was subsequently centrifuged at 6000 rpm for 20 minutes to
separate
solid material and cell wall fragments from liquid phase. The supernatant was
decanted and spun again as previously described. The clear supernatant was fed
onto a packed bed column containing cellulosic matrix (AvicelT'") as described
hereinabove. The CBM-protease attached specifically to the cellulosic matrix
and
after washing the column with 5 column volumes of high salt and low salt
washing buffers, respectively, the CBM-protease was eluted off the column
under
mild, non-denaturing conditions, i.e. with 1 M glucose solution in a single
peak.
The peak was subsequently concentrated using Millipore concentrators
(Ultrafree-
15 - Biomax-5).
Enterokinase activity is assayed using specific synthetic substrate according
to a
standard approach (Grant & Hermon-Taylor,1979): Synthetic substrate: Gly-Asp-
Asp-
Asp-Asp-Lys-a-naphthylamide (GD4K-na); Assay conditions 37°C.
Reaction
volume is 1.5 ml. The reaction mixture consists of :25 p1 10 mM GD~IC-na (0.5
mM), 125 NI 100 mM Tris-HCI, pH 8.4 (25 mM), 50 p1 100% DMSO (10%), 50 NI
100 mM CaCIZ (i0 mM), (20-100) p1 enterokinase, 250 NI distilled Hz0 -(20-100)
p1. The rate of ~3-naphthylamine formation was determined from the increment
of
fluorescence between a,ex=337 nm and ~,em=420 nm. This was monitored
continuously for 5 min.
23
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
The results from the activity measurements showed that CBM-enterokinase
produced and purified as described, was active; Enterokinase activity was
measured to be 442,7 cps/min/pg compared to blank 0,0001 cps/min/Ng.
The example shows firstly; that a protease-CBM can be produced in plants, in
this
case transiently in lettuce, and that CBM-protease can be isolated and
purified
successfully using the purification procedure described hereinabove. It
further
shows that the CBM9-2 affinity tag of the fusion protein is fully functional;
that
the CBM-protease effectively to cellulosic matrix and it can be eluted off the
matrix under the mild elution conditions described by the invention, and the
eluted protease is shown to be fully active. The enzymatically active purified
product provides in itself evidence for the non-denaturing properties of the
purification process, as enzyme activity is particularly sensitive for partial
or full
denaturation, which easily results in loss of activity. This shows effectively
that all
components of the invention are functional and that their behaviour and
performance is such that they can easily be applied in the manner described by
the invention hereinabove, resulting in a process constituting a major
improvement in specificity, economy and efficiency of downstream processing of
heterologous proteins of any source.
REFERENCES
Altschul et al., J. Mol. Biol. (1990) 215:403-i0.
Boraston et al. (2001) Biochemistry 40, pp.6240-6247.
Contributors (2001) in "Recombinant Protein Drugs" Ed. P. Buckel - from series-
Milestones in Drug Therapy, Birkhauser Verlag, Basel 2001.
Grant D.A., Hermon-Taylor J., Biochim. Biophys. Acta 567 (1979), 207-il.
Hammond (1999) in "Plant bioechnology; new products and applications" Eds.
Hammond, McGarvey & Yusibov, Springer Verlag, NY 1999.
HIC, RPC,IEX, Principles and Methods Series, nr.l8-1020-90, nr.l8-11134-
l6,nr.18-1114-21(respectively) - Amersham Pharmacia Biotech.
Kalyanpur M. (2000) in "Downstream processing of proteins" Ed. M.A. Desai
Humana Press N.J.
24
CA 02537102 2006-02-27
WO 2005/021762 PCT/IS2004/000010
Moloney M. (2000) in "Seed technology and its biological basis" Ed. M. Black
and
J.D. Bewley, Sheffield Academic Press, UK.
Paul G. Pau! Powell G. in Protein purification applications", Ed. by S.Roe,
"2nd
edition (2001).
R.K.Scopes R.K. (1993) in "Protein Purification: Principles and Practice" 3rd
ed.Springer-Verlag NY.
Shani et al. US Patent No. 6,331,416.
Winterhalter et. al. (1995) Mol. Microbiol. 15 (3), 431-444.
25
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPRI~:ND PLUS D'UN TOME.
CECI EST L,E TOME 1 DE 2
NOTE: Pour les tomes additionels, veillez contacter 1e Bureau Canadien des
Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
THIS IS VOLUME 1 OF 2
NOTE: For additional valumes please contact the Canadian Patent Office.
